본문 바로가기
KERD
논문KCI 등재

Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy

신의철|김경환|Chang Gon Kim
대한면역학회 (The Korean Association of Immunologists)|2020.02|Immune Network|제20권 제1호|pp. 1-15|DOI 10.4110/in.2020.20.e8

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

PrognosisBloodBiomarkersAdverse drug eventProgrammed cell death 1 ligand 1PD-1 receptor

초록

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.

Abstract

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.

참고문헌 (77)

  1. McLane LM, "CD8 T cell exhaustion during chronic viral infection and cancer", Annu Rev Immunol, 37, pp.457~495 (2019)
  2. Ribas A, "Cancer immunotherapy using checkpoint blockade", Science, 359, pp.1350~1355 (2018)
  3. Zajac AJ, "Viral immune evasion due to persistence of activated T cells without effector function", J Exp Med, 188, pp.2205~2213 (1998)
  4. Gallimore A, "Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes", J Exp Med, 187, pp.1383~1393 (1998)
  5. Hashimoto M, "CD8 T cell exhaustion in chronic infection and cancer : opportunities for interventions", Annu Rev Med, 69, pp.301~318 (2018)
  6. Blank CU, "Defining 'T cell exhaustion'", Nat Rev Immunol, 19, pp.665~674 (2019)
  7. Wherry EJ, "Molecular and cellular insights into T cell exhaustion", Nat Rev Immunol, 15, pp.486~499 (2015)
  8. Hargadon KM, "Immune checkpoint blockade therapy for cancer : an overview of FDA-approved immune checkpoint inhibitors", Int Immunopharmacol, 62, pp.29~39 (2018)
  9. 조주환, "Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles", Immune Network, 17(6), pp.378~391 (2017), 대한면역학회[DOI]
  10. Callahan MK, "Targeting T cell co-receptors for cancer therapy", Immunity, 44, pp.1069~1078 (2016)
  11. Sharma P, "Primary, adaptive, and acquired resistance to cancer immunotherapy", Cell, 168, pp.707~723 (2017)
  12. Baxi S, "Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs : systematic review and meta-analysis", BMJ, 360, pp.k793~ (2018)
  13. Wang DY, "Fatal toxic effects associated with immune checkpoint inhibitors : a systematic review and meta-analysis", JAMA Oncol, 4, pp.1721~1728 (2018)
  14. Champiat S, "Hyperprogressive disease : recognizing a novel pattern to improve patient management", Nat Rev Clin Oncol, 15, pp.748~762 (2018)
  15. Pitt JM, "Resistance mechanisms to immune-checkpoint blockade in cancer : tumor-intrinsic and-extrinsic factors", Immunity, 44, pp.1255~1269 (2016)
  16. Patel SP, "PD-L1 expression as a predictive biomarker in cancer immunotherapy", Mol Cancer Ther, 14, pp.847~856 (2015)
  17. Ilie M, "Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances : a potential issue for anti-PD-L1 therapeutic strategies", Ann Oncol, 27, pp.147~153 (2016)
  18. Hofman P, "PD-L1 immunohistochemistry for non-small cell lung carcinoma : which strategy should be adopted", Expert Rev Mol Diagn, 17, pp.1097~1108 (2017)
  19. Liu Y, "Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma", Clin Lung Cancer, 19, pp.e421~ (2018)
  20. Cristescu R, "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy", Science, 362, pp.eaar3593~ (2018)
  21. Lu S, "Comparison of biomarker modalities for predicting response to PD-1", PD-L1 checkpoint blockade : a systematic review and meta-analysis, 2019, pp.5, 1195~
  22. Petitprez F, "B cells are associated with survival and immunotherapy response in sarcoma", Nature, 577, pp.556~560 (2020)
  23. Cabrita R, "Tertiary lymphoid structures improve immunotherapy and survival in melanoma", Nature, 577, pp.561~565 (2020)
  24. Helmink BA, "B cells and tertiary lymphoid structures promote immunotherapy response", Nature, 577, pp.549~555 (2020)
  25. Gerlinger M, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing", N Engl J Med, 366, pp.883~892 (2012)
  26. Lesterhuis WJ, "Dynamic versus static biomarkers in cancer immune checkpoint blockade : unravelling complexity", Nat Rev Drug Discov, 16, pp.264~272 (2017)
  27. Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
  28. Simoni Y, "Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates", Nature, 557, pp.575~579 (2018)
  29. Thommen DS, "A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade", Nat Med, 24, pp.994~1004 (2018)
  30. Gros A, "Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients", Nat Med, 22, pp.433~438 (2016)
  31. Gros A, "Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes", J Clin Invest, 129, pp.4992~5004 (2019)
  32. Kim KH, "The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors", Clin Cancer Res, 25, pp.2144~2154 (2019)
  33. Kamphorst AO, "Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients", Proc Natl Acad Sci U S A, 114, pp.4993~4998 (2017)
  34. Huang AC, "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response", Nature, 545, pp.60~65 (2017)
  35. Huang AC, "A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma", Nat Med, 25, pp.454~461 (2019)
  36. Zappasodi R, "Non-conventional inhibitory CD4+Foxp3-PD-1hi T cells as a biomarker of immune checkpoint blockade activity", Cancer Cell, 33, pp.1017~1032 (2018)
  37. Juliá EP, "Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients", Cancer Immunol Immunother, 68, pp.1585~1596 (2019)
  38. Hopkins AC, "T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma", JCI Insight (2018)
  39. Han J, "TCR repertoire diversity of peripheral PD-1+CD8+ T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer", Cancer Immunol Res, 8, pp.146~154 (2020)
  40. Chen DS, "Oncology meets immunology : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
  41. Blank CU, "Cancer immunology. The cancer immunogram", Science, 352, pp.658~660 (2016)
  42. Zuazo M, "Functional systemic CD4 immunity is required for clinical responses to PD-L1", PD-1 blockade therapy, 2019, pp.11, e10293~
  43. Krieg C, "High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy", Nat Med, 24, pp.144~153 (2018)
  44. Kim HR, "The ratio of peripheral regulatory T cells to Lox-1+ polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer", Am J Respir Crit Care Med, 199, pp.243~246 (2019)
  45. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
  46. Bellmunt J, "Pembrolizumab as second-line therapy for advanced urothelial carcinoma", N Engl J Med, 376, pp.1015~1026 (2017)
  47. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375, pp.1856~1867 (2016)
  48. Powles T, "Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma(IMvigor211) : a multicentre, open-label, phase 3 randomised controlled trial", Lancet, 391, pp.748~757 (2018)
  49. Ferrara R, "Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1", PD-L1 inhibitors or with single-agent chemotherapy, 2018, pp.4, 1543~1552
  50. Champiat S, "Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1", PD-L1, 2017, pp.23, 1920~1928
  51. Saâda-Bouzid E, "Hyperprogression during anti-PD-1", PD-L1 therapy in patients with recurrent and, Ann Oncol, pp.2017, 28[DOI]
  52. Kato S, "Hyperprogressors after immunotherapy : analysis of genomic alterations associated with accelerated growth rate", Clin Cancer Res, 23, pp.4242~4250 (2017)
  53. Kim CG, "Hyperprogressive disease during PD-1", PD-L1 blockade in patients with non-small-cell lung cancer, 2019, pp.30, 1104~1113
  54. Kim Y, "Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor", J Thorac Oncol, 14, pp.1608~1618 (2019)
  55. Kamada T, "PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer", Proc Natl Acad Sci U S A, 116, pp.9999~10008 (2019)
  56. Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor", Immunity, 30, pp.899~911 (2009)
  57. Postow MA, "Immune-related adverse events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
  58. June CH, "Is autoimmunity the Achilles' heel of cancer immunotherapy", Nat Med, 23, pp.540~547 (2017)
  59. Wing K, "Regulatory T cells exert checks and balances on self tolerance and autoimmunity", Nat Immunol, 11, pp.7~13 (2010)
  60. Bettelli E, "T(H)-17 cells in the circle of immunity and autoimmunity", Nat Immunol, 8, pp.345~350 (2007)
  61. Walter U, "CD8+ T cells in autoimmunity", Curr Opin Immunol, 17, pp.624~631 (2005)
  62. Lipsky PE, "Systemic lupus erythematosus : an autoimmune disease of B cell hyperactivity", Nat Immunol, 2, pp.764~766 (2001)
  63. Kim KH, "Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment", OncoImmunology, 9, pp.e1722023~ (2020)
  64. Tracey D, "Tumor necrosis factor antagonist mechanisms of action : a comprehensive review", Pharmacol Ther, 117, pp.244~279 (2008)
  65. Haanen JBAG, "ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28, pp.iv119~iv142 (2017)
  66. Korn T, "IL-17 and Th17 cells", Annu Rev Immunol, 27, pp.485~517 (2009)
  67. Esfahani K, "Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade", N Engl J Med, 376, pp.1989~1991 (2017)
  68. Johnson D, "IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy", Cancer Immunol Res, 7, pp.860~865 (2019)
  69. Johnson DB, "Fulminant myocarditis with combination immune checkpoint blockade", N Engl J Med, 375, pp.1749~1755 (2016)
  70. Martinez-Calle N, "Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose : the role of occult pre-existing autoimmunity", Haematologica, 103, pp.e318~ (2018)
  71. Johnson DB, "A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis", Nat Med, 25, pp.1243~1250 (2019)
  72. Das R, "Early B cell changes predict autoimmunity following combination immune checkpoint blockade", J Clin Invest, 128, pp.715~720 (2018)
  73. Mammen AL, "Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1", Ann Rheum Dis, 78, pp.150~152 (2019)
  74. Kuehn HS, "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4", Science, 345, pp.1623~1627 (2014)
  75. Toi Y, "Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer", JAMA Oncol, 5, pp.376~383 (2019)
  76. Osorio JC, "Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer", Ann Oncol, 28, pp.583~589 (2017)
  77. Lim SY, "Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy", Clin Cancer Res, 25, pp.1557~1563 (2019)

관련 논문AI추천

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs고준영, 고지애, 구보미, 김경환, 박근칠, 선종무, 신의철, 안명주, 안진석, 이세훈, 조지현, 허준영대한면역학회 · Immune Network2020 · 제20권 제6호Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives김혜련, 임선민, Min Hee Hong대한면역학회 · Immune Network2020 · 제20권 제1호An update on immunotherapy with PD-1 and PD-L1 blockade고성애영남대학교 의과대학 · Journal of Yeungnam Medical Science2021 · 제38권 제4호DNA-protein biomarkers for immunotherapy in the era of precision oncology강소영, 김경미, 김빛내리대한병리학회 · Journal of Pathology and Translational Medicine2021 · 제55권 제1호Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors강다현, 권계철, 권인선, 김영철, 김진현, 박동일, 박철규, 선푸름, 신의철, 오인재, 이정은, 정재욱대한면역학회 · Immune Network2020 · 제20권 제3호Progressive accumulation of circulating CD27−CD28− effector/memory CD8+ T cells in patients with lung cancer blunts responses to immune checkpoint inhibitor therapyCho Hyun-Ju, Cho Jae-Ho, Jeong Saei, Kim Hee-Ok, Kim Young Ju, Lee Sung-Woo, Noh Jeong Eun, Oh In-Jae, Park Cheol-Kyu, Yun Ju Sik생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권

이 간행물의 다른 논문 (10건)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors이승룡, Juwhan Choipp. 1-21Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?박준용, Hye Won Lee, Kyung Joo Chopp. 1-14Re-defining T-Cell Exhaustion: Subset, Function, and Regulation하상준, Se Jin Impp. 1-19Coalition Forces of Immunologists and Oncologists for Defeating Cancer신의철, Deputy Editor, Immune Networkpp. 1-2Heterogeneity of Human γδ T Cells and Their Role in Cancer Immunity김태진, Hye Won Lee, Yun Shin Chungpp. 1-15
원문 보기